Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality
- PMID: 35677980
- PMCID: PMC9194544
- DOI: 10.5853/jos.2022.00752
Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality
Erratum in
-
Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality.J Stroke. 2024 Jan;26(1):129. doi: 10.5853/jos.2022.00752.e1. Epub 2024 Jan 30. J Stroke. 2024. PMID: 38326711 Free PMC article. No abstract available.
Abstract
Background and purpose: Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year.
Methods: We conducted a cross-sectional retrospective study of 171 stroke centers from 49 countries. We recorded COVID-19 admission volumes, CVT hospitalization, and CVT in-hospital mortality from January 1, 2019, to May 31, 2021. CVT diagnoses were identified by International Classification of Disease-10 (ICD-10) codes or stroke databases. We additionally sought to compare the same metrics in the first 5 months of 2021 compared to the corresponding months in 2019 and 2020 (ClinicalTrials.gov Identifier: NCT04934020).
Results: There were 2,313 CVT admissions across the 1-year pre-pandemic (2019) and pandemic year (2020); no differences in CVT volume or CVT mortality were observed. During the first 5 months of 2021, there was an increase in CVT volumes compared to 2019 (27.5%; 95% confidence interval [CI], 24.2 to 32.0; P<0.0001) and 2020 (41.4%; 95% CI, 37.0 to 46.0; P<0.0001). A COVID-19 diagnosis was present in 7.6% (132/1,738) of CVT hospitalizations. CVT was present in 0.04% (103/292,080) of COVID-19 hospitalizations. During the first pandemic year, CVT mortality was higher in patients who were COVID positive compared to COVID negative patients (8/53 [15.0%] vs. 41/910 [4.5%], P=0.004). There was an increase in CVT mortality during the first 5 months of pandemic years 2020 and 2021 compared to the first 5 months of the pre-pandemic year 2019 (2019 vs. 2020: 2.26% vs. 4.74%, P=0.05; 2019 vs. 2021: 2.26% vs. 4.99%, P=0.03). In the first 5 months of 2021, there were 26 cases of vaccine-induced immune thrombotic thrombocytopenia (VITT), resulting in six deaths.
Conclusions: During the 1st year of the COVID-19 pandemic, CVT hospitalization volume and CVT in-hospital mortality did not change compared to the prior year. COVID-19 diagnosis was associated with higher CVT in-hospital mortality. During the first 5 months of 2021, there was an increase in CVT hospitalization volume and increase in CVT-related mortality, partially attributable to VITT.
Keywords: COVID-19; Cerebral venous thrombosis; Mortality; SARS-CoV-2; Stroke; Vaccine-induced immune thrombotic thrombocytopenia.
Figures



Similar articles
-
Retrospective review COVID-19 vaccine induced thrombotic thrombocytopenia and cerebral venous thrombosis-what can we learn from the immune response.Clin Imaging. 2022 Oct;90:63-70. doi: 10.1016/j.clinimag.2022.06.020. Epub 2022 Jul 15. Clin Imaging. 2022. PMID: 35926315 Free PMC article.
-
Outcomes of Cerebral Venous Thrombosis due to Vaccine-Induced Immune Thrombotic Thrombocytopenia After the Acute Phase.Stroke. 2022 Oct;53(10):3206-3210. doi: 10.1161/STROKEAHA.122.039575. Epub 2022 Sep 9. Stroke. 2022. PMID: 36082668 Free PMC article.
-
Trends in cerebral venous thrombosis before and during the COVID-19 pandemic: Analysis of the National Inpatient Sample.J Stroke Cerebrovasc Dis. 2024 May;33(5):107651. doi: 10.1016/j.jstrokecerebrovasdis.2024.107651. Epub 2024 Feb 24. J Stroke Cerebrovasc Dis. 2024. PMID: 38408574
-
Thrombosis patterns and clinical outcome of COVID-19 vaccine-induced immune thrombotic thrombocytopenia: A Systematic Review and Meta-Analysis.Int J Infect Dis. 2022 Jun;119:130-139. doi: 10.1016/j.ijid.2022.03.034. Epub 2022 Mar 24. Int J Infect Dis. 2022. PMID: 35339716 Free PMC article.
-
Cerebral Venous Thrombosis in Patients With Heparin-Induced Thrombocytopenia a Systematic Review.Stroke. 2022 Jun;53(6):1892-1903. doi: 10.1161/STROKEAHA.121.036824. Epub 2022 Mar 4. Stroke. 2022. PMID: 35240862
Cited by
-
Reducing the global burden of cerebral venous thrombosis: An international research agenda.Int J Stroke. 2024 Jul;19(6):599-610. doi: 10.1177/17474930241242266. Epub 2024 Apr 9. Int J Stroke. 2024. PMID: 38494462 Free PMC article. Review.
-
Epidemiology, pathogenesis, and management of Coronavirus disease 2019-associated stroke.Front Med. 2023 Dec;17(6):1047-1067. doi: 10.1007/s11684-023-1041-7. Epub 2024 Jan 2. Front Med. 2023. PMID: 38165535 Review.
-
Cerebrovascular Disease in COVID-19.Viruses. 2023 Jul 21;15(7):1598. doi: 10.3390/v15071598. Viruses. 2023. PMID: 37515284 Free PMC article. Review.
-
Stroke in Asia.Cerebrovasc Dis Extra. 2024;14(1):58-75. doi: 10.1159/000538928. Epub 2024 Apr 26. Cerebrovasc Dis Extra. 2024. PMID: 38657577 Free PMC article. Review.
-
Genetic Testing Among Breast Cancer Patients in the Eastern Region of Saudi Arabia: Single-Center Experience.J Epidemiol Glob Health. 2024 Sep;14(3):1351-1357. doi: 10.1007/s44197-024-00296-4. Epub 2024 Sep 10. J Epidemiol Glob Health. 2024. PMID: 39256315 Free PMC article.
References
-
- Spudich S, Nath A. Nervous system consequences of COVID-19. Science. 2022;375:267–269. - PubMed
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous